James Flory

It was not. youtube.com/watch?v=WoW_0N…

@J_Hannah81 @KingaNYC @AdieChan1 @chemobrainfog I live in NYC and am quite fond of Domino's! Unfortunately have to run - thanks all!!

@AdieChan1 @chemobrainfog True, and you don't need to be sequenced! You can just eat some asparagus #F1000Talks

@KingaNYC @J_Hannah81 @ComiteMD @F1000 FDA may be major gatekeepter but they are still trying (hard) to lay out clear guidelines #F1000Talks

@chemobrainfog @AdieChan1 absolutely! and I don't think docs should be gatekeepers for many forms of consumer genetic testing. #F1000Talks

@chemobrainfog Agree! #patientcenteredoutcomes

@AdieChan1 There are very few doctors who can help a patient make sense of that data ... I wouldn't do it except for fun. #F1000Talks

@KingaNYC @J_Hannah81 @F1000 ... (2/2) time to interpret complex tests. That might eventually need to be incentivized #F1000Talks

@KingaNYC @J_Hannah81 @F1000 So far so good - we like being able to do a better job! - but long term it does take more (1/2) ... #F1000Talks

@F1000 @KB_Brolo Insurers will love any test showing an expensive drug doesn't work for certain ppl. Good for patients too. #F1000Talks

@J_Hannah81 @F1000 Lots of innovation! New regulatory frameworks and statistical approaches. Good times, but chaotic times #F1000Talks

@ScienceJobNYC @F1000 Good ?, and depends on the disease area. Oncology - maybe lack of subjects. Diabetes - just a cost issue #F1000Talks

@J_Hannah81 @F1000 Some applications can be cost saving - eg, new diagnostics that make thyroid cancer surgery unnecessary #F1000Talks

@F1000 Not a great idea, but good that it is legal. Medicine needs more consumer-driven innovation, as long as risks are acceptable #F1000

@F1000 Hard to decide how much to regulate! Do all tests need proof of benefit in a randomized trial, or are lower standards ok? #F1000Talks

@F1000 Clinical trials usually assume all people are the same. #precisionmed calls for bigger trials or novel study designs #F1000Talks

@F1000 Gleevec in oncology. In cardiovascular health: choice of blood thinner after heart attack based on patient genetics. #F1000talks

Using patient characteristics to determine drug choice. All health care providers practice it, but rarely based on good data #F1000talks

Our next #F1000Talks is on #personalizedmedicine - Weds 1pm EST/6pm GMT. Our guests are @J_Hannah81 & @Jamflo2k! f1000pri.me/en

"causality won’t be discarded, but it is being knocked off its pedestal as the primary fountain of meaning" #blendedmetaphor